AMENDMENTS TO THE CLAIMS

The following **Listing of Claims** will replace all prior versions, and listings of claims in the application.

1-78. **(Cancelled)**

79. **(New)** A compound having one of the following structures:



(a) **(b)** **(c)** ;

or pharmaceutically acceptable salt thereof;

wherein $\mathbf{R_1}$ and $\mathbf{R_2}$ are hydrogen or lower alkyl;

$\mathbf{R_3}$, $\mathbf{R_5}$ and $\mathbf{R_6}$ are $C_{1\text{-}6}$ alkyl;

the bond ····· is a single bond or a double bond;

$\mathbf{R_4}$ is halogen, $-OR^{4A}$, $-OC(=O)R^{4A}$ or $-NR^{4A}R^{4B}$; wherein R^{4A} and R^{4B} are independently hydrogen; a nitrogen protecting group selected from a carbamate, an amide, a cyclic imide derivative, an N-alkyl amine, an N-aryl amine, an imine derivative or an enamine derivative or an oxygen protecting group selected from a substituted methyl ether, a substituted ethyl ether, a substituted benzyl ether, a silyl ether, an ester, a carbonate, a cyclic acetal or a ketal; or R^{4A} and R^{4B}, taken together with the nitrogen atom to which they are attached, form a $C_{3\text{-}20}$ heterocyclic or $C_{3\text{-}14}$ heteroaryl moiety; or R_4, taken together with the carbon atom to which it is attached forms a moiety having the structure:  or



or R^{4A} and R^{4B} are independently a C_{1-6} alkyl group optionally substituted with one or more of C_{1-20} aliphatic; C_{3-14} aryl; C_{3-14} heteroaryl; C_{1-20} alkylC_{3-14}aryl; C_{1-20} alkylC_{3-14}heteroaryl, C_{3-14} aryloxy; C_{1-20} heteroalkoxy, C_{3-14} heteroaryloxy; C_{1-20} alkylthio; C_{3-14} arylthio; heteroC_{1-20}alkylthio; heteroC_{3-14}arylthio; F; Cl; Br; I; -OH; $-NO_2$; -CN; $-CF_3$; $-CH_2CF_3$; $-CHC1_2$; $-CH_2OH$; $-CH_2CH_2OH$; $-CH_2NH_2$; $-CH_2SO_2CH_3$; $-C(O)R_x$; $-CO_2(R_x)$; $-CON(R_x)_2$; $-OC(O)R_x$; $-OCO_2R_x$; $-OCON(R_x)_2$; $-N(R_x)_2$; $S(O)_2R_x$; $-NR_x(CO)R_x$ wherein each occurrence of R_x is independently C_{1-20} aliphatic, heteroC_{1-20}aliphatic, C_{3-14} aryl, C_{3-14} heteroaryl, C_{1-20} alkylC_{3-14}aryl or C_{1-20} alkylC_{3-14}heteroaryl;

$\mathbf{X_1}$ is O, S, NR^{X1} or $CR^{X1}R^{X2}$; wherein R^{X1} and R^{X2} are independently hydrogen, halogen, or a substituted or unsubstituted C_{1-20} alkyl, heteroC_{1-20}alkyl, cycloC_{3-10}alkyl, heterocyclo C_{3-10}alkyl, C_{3-14} aryl or C_{3-14} heteroaryl, or a nitrogen protecting group selected from a carbamate, an amide, a cyclic imide derivative, an N-alkyl amine, an N-aryl amine, an imine derivative or an enamine derivative;

Q is hydrogen, halogen, -CN, $-S(O)_{1-2}R^{Q1}$, $-NO_2$, $-COR^{Q1}$, $-CO_2R^{Q1}$, $-NR^{Q1}C(=O)R^{Q2}$, $-NR^{Q1}C(=O)OR^{Q2}$, $-CONR^{Q1}R^{Q2}$, or a substituted or unsubstituted C_{1-20} aliphatic, heteroC_{1-20}aliphatic, C_{3-20} alicyclic, heteroC_{3-20}alicyclic, C_{3-14} aryl or C_{3-14} heteroaryl moiety, or $-WR^{Q1}$; wherein W is independently O, S or NR^{Q3} and each occurrence of R^{Q1}, R^{Q2} and R^{Q3} is independently hydrogen, or a substituted or unsubstituted C_{1-20} aliphatic, heteroC_{1-20}aliphatic, C_{3-20} alicyclic, heteroC_{3-20} alicyclic, C_{3-14}aryl or C_{3-14} heteroaryl moiety;

$\mathbf{Y_2}$ is hydrogen, or a substituted or unsubstituted C_{1-20} alkyl, heteroC_{1-20}alkyl, cyclo C_{3-10}alkyl, heterocycloC_{3-10}alkyl, C_{3-14}aryl, or C_{3-14} heteroaryl moiety; or $-WR^{Y1}$;

W is O or NH; and

R^{Y1} and R^{Y2} are independently hydrogen, or a substituted or unsubstituted C_{1-20} aliphatic, heteroC_{1-20}aliphatic, C_{3-20} alicyclic, heteroC_{3-20}alicyclic, C_{3-14} aryl or C_{3-14} heteroaryl moiety;

wherein for the compound of formula (**a**), when $\mathbf{X^1}$ is O and the bond ····· is a double bond, **Q** is hydrogen, halogen, -CN, $-S(O)_{1-2}R^{Q1}$, $-NO_2$, $-COR^{Q1}$, $-CO_2R^{Q1}$, $-NR^{Q1}C(=O)R^{Q2}$, $-NR^{Q1}C(=O)OR^{Q2}$, $-CONR^{Q1}R^{Q2}$, or $-WR^{Q1}$; wherein W is independently O, S or NR^{Q3} and each occurrence of R^{Q1}, R^{Q2} and R^{Q3} is independently hydrogen, or a substituted or unsubstituted C_{1-20}

aliphatic, heteroC_{1-20}aliphatic, C_{3-20} alicyclic, heteroC_{3-20} alicyclic, C_{3-14}aryl or C_{3-14} heteroaryl moiety.

80. **(New)** The compound of claim 1 having one of the following structures:



(a) **(b)** **(c)**

or pharmaceutically acceptable salt thereof.

81. **(New)** The compound of claim 2, wherein the compound has the structure:


,

,

or

;

wherein n is 3; Y_2 and R^{Y1} are independently hydrogen or C_{1-6} alkyl; R_7 is a substituted or unsubstituted, linear or branched, cyclic or acyclic C_{1-6} alkyl moiety; R^{8B} is hydrogen or C_{1-6} alkyl; and X, Y and Z are independently a bond, -O-, -S-, -C(=O)-, -NR^{Z1}-, –$CHOR^{Z1}$, -$CHNR^{Z1}R^{Z2}$, C=S, C=N(R^{Y1}) or –CH(Hal); or a substituted or unsubstituted C_{0-6}alkylidene or C_{0-6}alkenylidene chain wherein up to two non-adjacent methylene units are independently optionally replaced by CO, CO_2, COCO, $CONR^{Z1}$, $OCONR^{Z1}$, $NR^{Z1}NR^{Z2}$, $NR^{Z1}NR^{Z2}CO$, $NR^{Z1}CO$, $NR^{Z1}CO_2$, $NR^{Z1}CONR^{Z2}$, SO, SO_2, $NR^{Z1}SO_2$, SO_2NR^{Z1}, $NR^{Z1}SO_2NR^{Z2}$, O, S, or NR^{Z1}; wherein Hal is a halogen selected from F, Cl, Br and I; and each occurrence of R^{Z1} and R^{Z2} is independently hydrogen, C_{1-20} alkyl, heteroC_{1-20} alkyl, C_{3-14} aryl, C_{3-14} heteroaryl or C_{1-20} acyl; or R^{Z1} and R^{Z2}, taken together with the nitrogen atom to which they are attached, form a heterocyclic or heteroaryl moiety;

or pharmaceutically acceptable salt thereof.

82. **(New)** The compound of claim 2, wherein the compound has the structure:


,

,

or

;

wherein n is 3; Y_2 and R^{Y1} are independently hydrogen or C_{1-6} alkyl; R_7 is a substituted or unsubstituted, linear or branched, cyclic or acyclic C_{1-6} alkyl moiety; R^{8B} is hydrogen or C_{1-6} alkyl; and Y is $–CHOR^{Y1}$, $-CHNR^{Y1}R^{Y2}$, C=O, C=S, $C=N(R^{Y1})$ or –CH(Hal); wherein Hal is a halogen selected from F, Cl, Br and I; and R^{Y1} and R^{Y2} are independently hydrogen, C_{1-20} alkyl, heteroC_{1-20} alkyl, C_{3-14} aryl, C_{3-14} heteroaryl or C_{1-20} acyl, or R^{Y1} and R^{Y2}, taken together with the nitrogen atom to which they are attached, form a heterocyclic or heteroaryl moiety;

or a pharmaceutically acceptable salt thereof.

83. **(New)** The compound of claim 2, wherein the compound has the structure:


,

,

or

;

wherein n is 3; Y_2 and R^{Y1} are independently hydrogen or C_{1-6} alkyl; R^{8B} is hydrogen or C_{1-6} alkyl; and R^Y is hydrogen, halogen, $-OR^{Y1}$ or $-NR^{Y1}NR^{Y2}$; wherein R^{Y1} and R^{Y2} are independently hydrogen, C_{1-20} alkyl, heteroC_{1-20} alkyl, C_{3-14} aryl, C_{3-14} heteroaryl or C_{1-20} acyl, or R^{Y1} and R^{Y2}, taken together with the nitrogen atom to which they are attached, form a heterocyclic or heteroaryl moiety;

or a pharmaceutically acceptable salt thereof.

84. **(New)** The compound of claim 80, wherein the compound has the structure:


,

,

or

;

wherein n is 3; Y_2 and R^{Y1} are independently hydrogen or C_{1-6} alkyl; R_7 is a substituted or unsubstituted, linear or branched, cyclic or acyclic C_{1-6} alkyl moiety; and R^{8B} is hydrogen or C_{1-6} alkyl;

or a pharmaceutically acceptable salt thereof.

85. **(New)** The compound of claim 79, wherein the compound has the structure:


,

,

;

;

wherein n is 3; and Y_2 and R^{Y1} are independently hydrogen or C_{1-6} alkyl;

or a pharmaceutically acceptable salt thereof.

86. **(New)** The compound of claim 79, wherein the compound has the structure:



wherein n is 3; and R^{Y1} and R^{Y2} are independently hydrogen or C_{1-6} alkyl;
or a pharmaceutically acceptable salt thereof.

87. **(New)** The compound of claim 80, wherein the compound has one of the following structures:



W is O or NH;

R^{Y1} is hydrogen, or a substituted or unsubstituted C_{1-20} aliphatic, heteroC_{1-20}aliphatic, C_{3-20} alicyclic, heteroC_{3-20} alicyclic, C_{3-14} aryl or C_{3-14} heteroaryl moiety;

R_7 is a substituted or unsubstituted C_{1-6} alkyl or heteroC_{1-6}alkyl moiety;

R_8 is a substituted or unsubstituted C_{1-20} alkyl, heteroC_{1-20}alkyl, cycloC_{3-20}alkyl, heterocycloC_{3-20}alkyl, C_{3-14} aryl or C_{3-14} heteroaryl moiety; and Alk is a substituted or unsubstituted C_{0-6}alkylidene or C_{0-6}alkenylidene chain wherein up to two non-adjacent

methylene units are independently optionally replaced by CO, CO_2, COCO, $CONR^{Z1}$, $OCONR^{Z1}$, $NR^{Z1}NR^{Z2}$, $NR^{Z1}NR^{Z2}CO$, $NR^{Z1}CO$, $NR^{Z1}CO_2$, $NR^{Z1}CONR^{Z2}$, SO, SO_2, $NR^{Z1}SO_2$, SO_2NR^{Z1}, $NR^{Z1}SO_2NR^{Z2}$, O, S, or NR^{Z1}; wherein each occurrence of R^{Z1} and R^{Z2} is independently hydrogen, C_{1-20} alkyl, heteroC_{1-20} alkyl, C_{3-14} aryl, C_{3-14} heteroaryl or C_{1-20} acyl; wherein for compounds of formula (**a**), when $\mathbf{X^1}$ is O, the bond ····· is a single bond; or a pharmaceutically acceptable salt thereof.

88. **(New)** The compound of claim 80, wherein the compound has one of the following structures:



,


,


or


;

wherein Y_2 and R^{Y1} are independently hydrogen or C_{1-6} alkyl;
or a pharmaceutically acceptable salt thereof.

89. **(New)** The compound of claim 80, wherein the compound has one of the following structures:



or

;

wherein Y_2 and R^{Y1} are independently hydrogen or C_{1-6} alkyl; R_7 is a substituted or unsubstituted, linear or branched, cyclic or acyclic C_{1-6} alkyl moiety; R^{8B} is hydrogen or C_{1-6} alkyl; and X, Y and Z are independently a bond, -O-, -S-, -C(=O)-, $-NR^{Z1}-$, $-CHOR^{Z1}$, $-CHNR^{Z1}R^{Z2}$, C=S, $C=N(R^{Y1})$ or –CH(Hal); or a substituted or unsubstituted C_{0-6}alkylidene or C_{0-6}alkenylidene chain wherein up to two non-adjacent methylene units are independently optionally replaced by CO, CO_2, COCO, $CONR^{Z1}$, $OCONR^{Z1}$, $NR^{Z1}NR^{Z2}$, $NR^{Z1}NR^{Z2}CO$, $NR^{Z1}CO$, $NR^{Z1}CO_2$, $NR^{Z1}CONR^{Z2}$, SO, SO_2, $NR^{Z1}SO_2$, SO_2NR^{Z1}, $NR^{Z1}SO_2NR^{Z2}$, O, S, or NR^{Z1}; wherein Hal is a halogen selected from F, Cl, Br and I; and each occurrence of R^{Z1} and R^{Z2} is independently hydrogen, C_{1-20} alkyl, heteroC_{1-20}alkyl, C_{3-14} aryl, C_{3-14} heteroaryl or C_{1-20} acyl; or R^{Z1} and R^{Z2}, taken together with the nitrogen atom to which they are attached, form a C_{3-20} heterocyclic or C_{3-14} heteroaryl moiety;

or a pharmaceutically acceptable salt thereof.

90. **(New)** The compound of claim 80, wherein the compound has one of the following structures:



,



or



;

Y_2 and R^{Y1} are independently hydrogen or C_{1-6} alkyl;

R_7 is a substituted or unsubstituted, linear or branched, cyclic or acyclic C_{1-6} alkyl moiety; R^{8B} is hydrogen or C_{1-6} alkyl; and Y is –$CHOR^{Y1}$, -$CHNR^{Y1}R^{Y2}$, C=O, C=S, C=N(R^{Y1}) or –CH(Hal); wherein Hal is a halogen selected from F, Cl, Br and I; and R^{Y1} and R^{Y2} are independently hydrogen, C_{1-20} alkyl, heteroC_{1-20}alkyl, C_{3-14} aryl, C_{3-14} heteroaryl or C_{1-20} acyl, or R^{Y1} and R^{Y2}, taken together with the nitrogen atom to which they are attached, form a C_{3-20} heterocyclic or C_{3-14} heteroaryl moiety;

or a pharmaceutically acceptable salt thereof.

91. **(New)** The compound of claim 80, wherein the compound has one of the following structures:



or

;

wherein Y_2 and R^{Y1} are independently hydrogen or C_{1-6} alkyl;

R^{8B} is hydrogen or C_{1-6} alkyl; and R^Y is hydrogen, halogen, -OR^{Y1} or –$NR^{Y1}NR^{Y2}$; wherein R^{Y1} and R^{Y2} are independently hydrogen, C_{1-20} alkyl, heteroC_{1-20}alkyl, C_{3-14} aryl, C_{3-14} heteroaryl or C_{1-20} acyl, or R^{Y1} and R^{Y2}, taken together with the nitrogen atom to which they are attached, form a C_{3-20} heterocyclic or C_{3-14} heteroaryl moiety;

or a pharmaceutically acceptable salt thereof.

92. **(New)** The compound of claim 80, wherein the compound has one of the following structures:



or

;

wherein Y_2 and R^{Y1} are independently hydrogen or C_{1-6} alkyl;

R_7 is a substituted or unsubstituted, linear or branched, cyclic or acyclic C_{1-6} alkyl moiety; and R^{8B} is hydrogen or C_{1-6} alkyl;

or a pharmaceutically acceptable salt thereof.

93. **(New)** The compound of claim 79, wherein the compound has one of the following structures:


,

,

or

;

wherein Y_2 and R^{Y1} are independently hydrogen or C_{1-6} alkyl;

or a pharmaceutically acceptable salt thereof.

94. **(New)** The compound of claim 79, wherein the compound has one of the following structures:



;


;


or


;

and R^{Y1} and R^{Y2} are independently hydrogen or C_{1-6} alkyl;

or a pharmaceutically acceptable salt thereof.

95. **(New)** The compound of claim 79, wherein R_1 and R_2 are each hydrogen.

96. **(New)** The compound of claim 79, wherein R_3 is C_{1-6} alkyl.

97. **(New)** The compound of claim 96, wherein R_3 is methyl.

98. **(New)** The compound of claim 79, wherein R_5 and R_6 are each methyl;

R_4 is OH, OAc, NH_2 or halogen, or R_4 taken together with the carbon atom to which it is attached forms a moiety having the structure: 

.

99. **(New)** The compound according to any one of claims 81 or 89, wherein R_7 is C_{1-6} alkyl.

100. **(New)** The compound according to claim 99, wherein R_7 is methyl.

101. **(New)** The compound according to claim 79 of formula (**b**) or (**c**) or the compound of formula (**a**) wherein when $\mathbf{X^1}$ is O, the bond ····· is a single bond, wherein Q has the structure:



;

wherein R_7 is a substituted or unsubstituted, linear or branched, cyclic or acyclic C_{1-6} alkyl moiety; R_8 is a substituted or unsubstituted C_{3-20} carbocyclic, C_{3-20} heterocyclic, C_{3-14} aryl or C_{3-14} heteroaryl moiety; and X, Y and Z are independently a bond, -O-, -S-, -C(=O)-, -NR^{Z1}-, -$CHOR^{Z1}$, -$CHNR^{Z1}R^{Z2}$, C=S, C=N(R^{Y1}) OR –CH(Hal); or a substituted or unsubstituted C_{0-6}alkylidene or C_{0-6}alkenylidene chain where up to two non-adjacent methylene units are independently optionally replaced by CO, CO_2, COCO, $CONR^{Z1}$, $OCONR^{Z1}$, $NR^{Z1}NR^{Z2}$, $NR^{Z1}NR^{Z2}CO$, $NR^{Z1}CO$, $NR^{Z1}CO_2$, $NR^{Z1}CONR^{Z2}$, SO, SO_2, $NR^{Z1}SO_2$, SO_2NR^{Z1}, $NR^{Z1}SO_2NR^{Z2}$, O, S, or NR^{Z1}; wherein Hal is a halogen selected from F, Cl, Br and I; and each occurrence of R^{Z1} and R^{Z2} is independently hydrogen, C_{1-20} alkyl, heteroC_{1-20}alkyl, C_{3-14} aryl, C_{3-14} heteroaryl or C_{1-20} acyl; or R^{Z1} and R^{Z2}, taken together with the nitrogen atom to which they are attached, form a C_{3-20} heterocyclic or C_{3-14} heteroaryl moiety.

102. **(New)** The compound according to claim 79 of formula (**b**) or (**c**) or the compound of formula (**a**) wherein when $\mathbf{X^1}$ is O, the bond ····· is a single bond, wherein Q has the structure:



wherein R_7 is a substituted or unsubstituted, linear or branched, cyclic or acyclic C_{1-6} alkyl moiety; R_8 is a substituted or unsubstituted C_{3-20} carbocyclic, C_{3-20} heterocyclic, C_{3-14} aryl or C_{3-14} heteroaryl moiety; and R^Y is hydrogen, halogen, -OR^{Y1} or –$NR^{Y1}NR^{Y2}$; wherein R^{Y1} and R^{Y2} are independently hydrogen, C_{1-20} alkyl, heteroC_{1-20}alkyl, C_{3-14}aryl, C_{3-14} heteroaryl or C_{1-20} acyl, or R^{Y1} and R^{Y2}, taken together with the nitrogen atom to which they are attached, form a C_{3-20} heterocyclic or C_{3-14} heteroaryl moiety.

103. **(New)** The compound of any one of claims 87, 98, or 99, wherein R_8 is one of:


;

wherein p is an integer from 0 to 5, as valency allows; q is 1 or 2, r is an integer from 1 to 6; each occurrence of R^{8A} is independently hydrogen, C_{1-20} alkyl, heteroC_{1-20}alkyl, C_{3-14} aryl, C_{3-14} heteroaryl, -(C_{1-20} alkyl)C_{3-14} aryl or -(C_{1-20} alkyl)C_{3-14}heteroaryl, $-OR^{8C}$, $-SR^{8C}$, $-N(R^{8C})_2$, $-SO_2N(R^{8C})_2$, $-(C=O)N(R^{8C})_2$, halogen, -CN, $-NO_2$, $-(C=O)OR^{8C}$, $-N(R^{8C})(C=O)R^{8D}$, wherein each occurrence of R^{8C} and R^{8D} is independently hydrogen, C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{3-14} aryl, C_{3-14} heteroaryl, -(C_{1-20} alkyl)C_{1-20} aryl or -(C_{1-20} alkyl)C_{3-14} heteroaryl; and each occurrence of R^{8B} is independently hydrogen or C_{1-6} alkyl.

104. **(New)** The compound of claim 103, wherein R_8 has the structure:


;

wherein R^{8B} is hydrogen or C_{1-6} alkyl.

105. **(New)** The compound of claim 80 or 87, wherein Y_2 is C_{1-6} alkyl and R^{Y1} is hydrogen or C_{1-6} alkyl.

106. **(New)** The compound of claim 80 or 87, wherein R^{Y1} is H and Y_2 is CF_3.

107. **(New)** The compound of claim 94, wherein R_4 is hydroxyl, $C_{1\text{-}6}$ alkoxy, acyloxy, amino or halogen, or R_4 taken together with the carbon atom to which it is attached forms a moiety having the structure:  ; wherein R^{Y1} and R^{Y2} are independently hydrogen, $C_{1\text{-}6}$ alkyl, $C_{3\text{-}14}$ aryl or $C_{3\text{-}14}$ heteroaryl.

108. **(New)** The compound of claim 94, wherein R_4 is OH, OAc, NH_2 or F, or R_4 taken together with the carbon atom to which it is attached forms a moiety having the structure:  .

109. **(New)** The compound of claim 94, wherein the stereocenter  has the following stereochemistry:  .

110. **(New)** The compound of claim 94, wherein the stereocenter  has the following stereochemistry:  .

111. **(New)** The compound of claim 94, wherein R_3, R_5 and R_6 are each methyl and R_4 is OH, OAc, NH_2 or F, or R_4 taken together with the carbon atom to which it is attached forms a moiety having the structure:  ; and the stereocenter  has the following stereochemistry  .

112. **(New)** The compound according to claim 79, wherein the compound is selected from:



; or



;

or



;

or a pharmaceutically acceptable salt thereof.

113. **(New)** A compound having the formula



or pharmaceutically acceptable salt thereof.

114. **(New)** A compound having the structure:



or pharmaceutically acceptable salt thereof;

wherein $\mathbf{R_1}$ and $\mathbf{R_2}$ are each independently hydrogen

$\mathbf{R_3}$, $\mathbf{R_5}$ and $\mathbf{R_6}$ are $C_{1\text{-}6}$ alkyl;

$\mathbf{R_4}$ is halogen, $-OR^{4A}$, $-OC(=O)R^{4A}$ or $-NR^{4A}R^{4B}$; wherein R^{4A} and R^{4B} are independently hydrogen, or substituted or unsubstituted $C_{1\text{-}6}$ alkyl; a nitrogen protecting group selected from a carbamate, an amide, a cyclic imide derivative, an N-alkyl amine, an N-aryl amine, an imine derivative or an enamine derivative or an oxygen protecting group selected from a methyl ether, a substituted methyl ether, a substituted ethyl ether, a substituted benzyl ether, a silyl ether, an ester, a carbonate, a cyclic acetal or a ketal; or R^{4A} and R^{4B}, taken together with the nitrogen atom to which they are attached, form a $C_{3\text{-}20}$ heterocyclic or $C_{3\text{-}14}$ heteroaryl moiety; or R_4, taken together with the carbon atom to which it is attached forms a moiety having the structure:



;

$\mathbf{X_1}$ is O, S, NR^{X1} or $CR^{X1}R^{X2}$; wherein R^{X1} and R^{X2} are independently hydrogen, halogen, or substituted or unsubstituted $C_{1\text{-}20}$ alkyl, hetero$C_{1\text{-}20}$alkyl, cyclo$C_{3\text{-}10}$alkyl, heterocyclo $C_{3\text{-}10}$alkyl, $C_{3\text{-}14}$ aryl or $C_{3\text{-}14}$ heteroaryl, or a nitrogen protecting group selected from a carbamate, an amide, a cyclic imide derivative, an N-alkyl amine, an N-aryl amine, an imine derivative or an enamine derivative; and

$\mathbf{Y_1}$ and $\mathbf{Y_2}$ are independently hydrogen, or a substituted or unsubstituted $C_{1\text{-}20}$ alkyl, hetero$C_{1\text{-}20}$alkyl, cyclo $C_{3\text{-}10}$alkyl, heterocyclo$C_{3\text{-}10}$alkyl, $C_{3\text{-}14}$aryl, or $C_{3\text{-}14}$ heteroaryl moiety; or $-WR^{Y1}$; wherein W is independently –O-, -S- or NR^{Y2} wherein each occurrence of R^{Y1} and R^{Y2}

is independently hydrogen or an C_{1-20} alkyl, heteroC_{1-20}alkyl, cycloC_{3-10}alkyl, heterocycloC_{3-10}alkyl, C_{3-14} aryl or C_{3-14} heteroaryl moiety; or $\mathbf{Y_1}$ and $\mathbf{Y_2}$ together with the carbon atom to which they are attached form a moiety having the structure:  , or  .

115. **(New)** The compound of claim 114 having the structure:



wherein n is 3; and $\mathbf{Y_1}$ and $\mathbf{Y_2}$ are independently hydrogen, C_{1-6}alkyl, or CF_3.

116. **(New)** The compound of claim 114 having the structure:

 ;

wherein $\mathbf{Y_1}$ and $\mathbf{Y_2}$ are independently hydrogen, C_{1-6}alkyl, or CF_3.

117. **(New)** The compound of claim 115 or 116, wherein R_5 and R_6 are each methyl.

118. **(New)** The compound of claim 115 or 116, wherein R_3 is lower alkyl.

119. **(New)** The compound of claim 118, wherein R_3 is methyl.

120. **(New)** The compound of claim 115 or 116, wherein R_4 is OH, OAc, NH_2 or halogen.

121. **(New)** A pharmaceutical composition comprising:

a pharmaceutically acceptable carrier, adjuvant or vehicle; and

a compound according to any one of claims 79, 112, 113, or 114, or a pharmaceutically acceptable salt thereof.

122. **(New)** The pharmaceutical composition of claim 121, further comprising a cytotoxic agent.

123. **(New)** The pharmaceutical composition of claim 122, wherein the cytotoxic agent is an anticancer agent.

124. **(New)** The pharmaceutical composition of claim 123, wherein the anticancer agent is 12,13-desoxyepothilone B, (E)-9,10-dehydro-12,13-desoxyEpoB, 26-CF3-(E)-9,10-dehydro-12,13-desoxyEpoB, taxol, radicicol orTMC-95A/B.

125. **(New)** The pharmaceutical composition of claim 121, further comprising a palliative agent.